Novaremed, a privately held clinical-stage biopharmaceutical company, expands its pipeline of non-opioid treatment candidates for chronic pain indications through the acquisition of Metys Pharmaceuticals. The acquisition broadens Novaremed’s existing pipeline by adding both clinical and preclinical development projects based on an innovative approach for non-opioid chronic pain treatment.

VISCHER AG advises Novaremed with a team led by Matthias Staehelin with Vincent Reardon, Luzius Zumstein, Cédric Saladin (all Corporate) and Nadia Tarolli with Adrian Briner (both Tax).

Press release